Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201654 | 0.80 | TLR9 (0.37) | HRH1HTR6TLR9TLR8TLR7 | |
| SCHEMBL16201666 | 0.77 | CYP1A2 (0.43) | HRH1HTR6HTR1AHTR2AHTR2B | |
| SCHEMBL16201637 | 0.76 | FEN1 (0.35) | TLR9TLR8TLR7KDM4EALDH1A1 | |
| SCHEMBL16201636 | 0.74 | PDE4A (0.36) | TLR9TLR8TLR7ALDH1A1FEN1 | |
| SCHEMBL16201641 | 0.72 | FEN1 (0.36) | TLR9TLR8TLR7FEN1 | |
| SCHEMBL16201655 | 0.70 | PDE4A (0.41) | TLR9TLR8TLR7FEN1 | |
| SCHEMBL16201633 | 0.69 | TLR8 (0.38) | TLR9TLR8TLR7ALDH1A1FEN1 | |
| SCHEMBL29302055 | 0.67 | FEN1 (0.44) | TLR9TLR8TLR7KCNH2FEN1 | |
| SCHEMBL24101726 | 0.67 | CYP1A2 (0.44) | HRH1HTR6HTR1AHTR2AHTR2B | |
| SCHEMBL30339398 | 0.67 | CYP1A2 (0.44) | HRH1HTR6HTR1AHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345905-B2 | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | BETA PHARMA CANADA INC. (CA) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322229-A1 | HETEROCYCLIC AMIDES COMPOUNDS WHICH ARE HDAC6 INHIBITORS AND USED AS ANTI-TUMORAL AGENTS | HDAC6, HDAC1, HDAC7 | HRH1 677/4885HTR6 4306/4885TLR9 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.